Doses Of Sodium Bicarbonate Research Articles

Effect of Preharvest Treatments with Sodium Bicarbonate and Potassium Silicate in Navel and Valencia Oranges to Control Fungal Decay and Maintain Quality Traits during Cold Storage

The quality of sweet orange (Citrus sinensis L.) is determined by the presence of decay caused by phytopathogenic fungi. This can develop in the field and rapidly spread among oranges during postharvest storage. Currently, the conventional treatments applied to control this problem are chemical fungicides. However, consumers demand eco-friendly and non-polluting alternatives with low chemical residues. Therefore, the aim of this work is the preharvest application of sodium bicarbonate (SB) and potassium silicate (PS) solutions at 0.1 and 1% to Navel and Valencia oranges to elucidate the effect on fruit quality and fungal decay at harvest and after 42 days of storage at 8 °C. Results showed that oranges treated with SB 0.1%, PS 0.1, and PS 1% maintained quality traits at similar levels to the control ones. However, SB 1% reduced firmness and increased weight loss, respiration rate, maturity index, and citrus color index. The total carotenoid content significantly increased in oranges treated with SB 1%, and no differences were observed in the other treatments compared to the control. Total antioxidant activity and total phenolic content decreased in oranges treated with SB at 0.1 and 1%, contrary to the results observed in oranges treated with PS, where both parameters increased. Regarding fungal decay, the best results were obtained in oranges treated with the highest doses of SB and PS. Therefore, the use of SB and PS in preharvest sprays could be an alternative to control fungal decay without affecting orange quality.

Sodium Bicarbonate Ingestion in a Fasted State Improves 16.1-km Cycling Time-Trial Performance.

The use of sodium bicarbonate (SB) as a preexercise ergogenic aid has been extensively studied in short-duration high-intensity exercise. Very few studies have considered the effects of SB ingestion before prolonged high-intensity exercise. The aim of the present study was to determine the effects of a 0.3 g·kg -1 body mass dose of SB ingested before the start of a 16.1-km cycling time trial in cyclists. Ten trained male cyclists (age, 31.1 ± 9 yr; height, 1.84 ± 0.05 m; body mass, 82.8 ± 8.5 kg; and V̇O 2peak , 60.4 ± 3.1 mL·kg -1 ·min -1 ) completed this study. Participants ingested 0.3 g·kg -1 in gelatine (SB-G) and enteric capsules (SB-E) 1 wk apart to determine individualized time-to-peak alkalosis for each ingestion form. Using a randomized crossover design, participants then performed simulated 16.1-km time trials after ingestion of SB-G, SB-E, or a placebo. There were significant differences in performance between the SB and placebo ingestion strategies ( f = 5.50, P = 0.014, p η2 = 0.38). Performance time was significantly improved by SB ingestion (mean improvement: 34.4 ± 42.6 s ( P = 0.031) and 40.4 ± 45.5 s ( P = 0.020) for SB-G and SB-E, respectively) compared with the placebo. Gastrointestinal symptoms were lower after SB-E compared with SB-G (36.3 ± 4.5 vs 5.6 ± 3.1 AU, P < 0.001, g = 7.09). This study demonstrates that increased buffering capacity after acute preexercise SB ingestion can improve endurance cycling time-trial performances. The use of SB could be considered for use in 16.1-km cycling time trials, but further work is required to establish these effects after a preexercise meal.

Decompensated metabolic acidosis in the emergency department: Epidemiology, sodium bicarbonate therapy, and clinical outcomes

ObjectiveThis article aims to describe the epidemiology of decompensated metabolic acidosis, the characteristics of sodium bicarbonate (SB) administration and outcomes in emergency department (ED) patients. DesignThis is a retrospective cohort study. SettingED of a tertiary referral hospital in Melbourne, Australia. ParticipantsAdult patients presenting to the ED between 1 July 2011 and 20 September 2020 with decompensated metabolic acidosis diagnosed on arterial blood gas (ABG). Main outcome measuresWe compared characteristics between those treated with or without SB. We studied SB administration characteristics, change in laboratory variables, factors associated with use and dose, and clinical outcomes. ResultsAmong 753,613 ED patients, 314 had decompensated metabolic acidosis on ABG, with 17.8% receiving SB. Patients in the SB group had lower median pH, CO2, bicarbonate, and base excess (BE) levels compared with the No SB group (P < 0.01). The median number of SB doses in the SB group was one treatment. This was given at a median total dose of 100 mmol and at a median of 2.8 h after the diagnostic blood gas results. Only 42% of patients in the SB group had a subsequent blood gas measured. In such patients, there was no significant change in pH, bicarbonate, or BE. SB therapy was not independently associated with mortality. ConclusionsABG-confirmed decompensated metabolic acidosis was rare but associated with a high mortality. SB administration occurred in a minority of patients and in more acidaemic patients. However, SB dose was stereotypical and not tailored to acidosis severity. Assessment of SB effect was infrequent and showed no correction of acidosis. Systematic studies of titrated SB therapy are required to inform current practice.

The interplay between bicarbonate kinetics and gastrointestinal upset on ergogenic potential after sodium bicarbonate intake: a randomized double-blind placebo-controlled trial

This double-blind placebo-controlled cross-over study utilized comprehensive monitoring of blood bicarbonate (HCO3¯) kinetics and evaluation of gastrointestinal (GI) upset to determine their impact on an ergogenic potential of sodium bicarbonate (SB) co-ingested with carbohydrate (CHO). Nineteen CrossFit athletes performed 6 bouts of 15 s Wingate Anaerobic Test (WAnT) 90 min post-ingestion of 0.4 g·kg−1 body mass (BM) of SB (SB + CHO treatment) or PLA (PLA + CHO treatment) with 15 g CHO. Blood HCO3¯ concentration was evaluated at baseline, 30-, 60-, 75- and 90 min post-ingestion, in between WAnT bouts, and 3 and 45 min post-exercise, while GI upset at 120 min after protocol started. Control (no supplementation; CTRL) procedures were also performed. An effective elevation of extra-cellular buffering capacity was observed 60–90 min post-ingestion of SB + CHO. At mean peak blood HCO3¯, or at start of exercise an increase > 6 mmol·L−1 in HCO3¯ was noted in 84% and 52.6% participants, respectively. SB + CHO did not prevent performance decrements in WAnT bouts. There were no significant relationships between changes in blood HCO3¯ and WAnTs’ performance. Total GI was significantly higher in SB + CHO compared to CTRL, and stomach problems in SB + CHO compared to CTRL and PLA + CHO. There were inverse associations between peak- (p = 0.031; r = − 0.495), average- (p = 0.002; r = − 0.674) and minimum power (p = 0.008; r = − 0.585) and total GI upset, as well as average power and severe GI distress (p = 0.042; r = − 0.471) at SB + CHO. The implemented dose of SB + CHO was effective in improving buffering capacity, but did not prevent decrements in WAnTs’ performance. GI side effects were crucial in affecting the ergogenic potential of SB and thus must be insightfully monitored in future studies.

Effect of Sodium Bicarbonate on Systolic Blood Pressure in CKD: A Systematic Review and Meta-Analysis.

Individuals with CKD are at a higher risk of cardiovascular morbidity and mortality. Acidosis is positively correlated with CKD progression and elevated systolic BP. Sodium bicarbonate is an efficacious treatment of acidosis, although this may also increase systolic BP. In this systematic review and meta-analysis, we summarize the evidence evaluating systolic BP and antihypertensive medication change (which may indicate systolic BP change) in response to sodium bicarbonate therapy in individuals with CKD. Medical Literature Analysis and Retrieval System Online, Excerpta Medica database, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, Cochrane Central Register of Controlled Trials, and World Health Organization (WHO) trials registry databases were searched for randomized control trials where sodium bicarbonate was compared with placebo/usual care in CKD stage G1-5 non-dialysis-dependent populations. Random effects meta-analyses were used to evaluate changes in systolic BP and BP-modifying drugs after sodium bicarbonate intervention. Fourteen randomized control trials (2110 individuals, median follow-up 27 [interquartile range 97] weeks, mean age 60 [SD 10] years, mean systolic BP 136 [SD 17] mm Hg, mean eGFR 38 [SD 10] ml/min, mean serum bicarbonate 22 [SD 4] mmol/L) were eligible for inclusion. Meta-analysis suggested that sodium bicarbonate did not influence systolic BP in individuals with CKD stage G1-5. Results were consistent when stratifying by dose of sodium bicarbonate or duration of intervention. Similarly, there was no significant increase in the use of antihypertensive medication or diuretics in individuals taking sodium bicarbonate, whereas there was a greater decrease in antihypertensive medication use in individuals taking sodium bicarbonate compared with controls. Our results suggest, with moderate certainty, that sodium bicarbonate supplementation does not adversely affect systolic BP in CKD or negatively influence antihypertensive medication requirements.

Effects of Sodium Bicarbonate Ingestion on Recovery in High-Level Judokas.

Background: The aim of this study was to examine the sodium bicarbonate (NaHCO3) effect on recovery in high-level judokas. Methods: The sample of participants consisted of 10 male judokas (Age = 20 ± 2.1 years) who are judo masters (black belt holders) with a minimum of 10 years of training and competition experience. The study was designed as a double-blinded crossover design with the order of treatments being randomly assigned. The washout period was 72 h. All subjects received a dose of sodium bicarbonate (0.3 g/kg body weight) or a placebo 120 min before the fatigue caused by the special judo fitness test (SJFT). Lactate concentration (LC), countermovement jump (CMJ), hand grip strength and degree of perceived fatigue on Borg’s scale (RPE) were tested two times before SJFT and four times after SJFT. Results: There was no interaction between groups and type of recovery at any time during the two types of recovery for RPE, grip strength, VJ and lactate concentration (p > 0.05). However, there was a main effect of time for dominant grip strength (F(1,8)= 3.3; p = 0.01; η2 = 0.25, (small)), non-dominant grip strength (F(1,8) = 3.2; p = 0.01; η2 = 0.24, (small)), CMJ (F(1,8) = 8.8; p = 0.01; η2 = 0.47, (small)), and LC (F(1,8) = 124.2; p = 0.001; η2 = 0.92, (moderate)). Conclusions: The results of the present study show no significant difference between the NaHCO3 and placebo groups in RPE, handgrip strength, CMJ, and lactate concentration.

A case of osmotic demyelination syndrome presumably related to the administration of multiple doses of sodium bicarbonate

A case of osmotic demyelination syndrome presumably related to the administration of multiple doses of sodium bicarbonate

Effect of Oral Sodium Bicarbonate Treatment on 24-Hour Ambulatory Blood Pressure Measurements in Patients With Chronic Kidney Disease and Metabolic Acidosis.

Background: Sodium bicarbonate supplementation is a mainstay in the treatment of metabolic acidosis in patients with chronic kidney disease (CKD). Recent studies showed reduction of progression of CKD and reduced all-cause mortality. However, additional sodium loading could worsen arterial hypertension, a well-known contributor to progression of CKD. This patient-relevant and economically negative side effect is under-studied in prospective studies up until now.Objective: The aim of this study was to analyze the effect of sodium bicarbonate treatment on arterial blood pressure at baseline and after 8 weeks.Methods: The SoBic study is an ongoing randomized controlled trial, in which patients with CKD receive either a high dose of oral sodium bicarbonate or a rescue treatment, if necessary. We used standardized office blood pressure and 24-hour ambulatory blood pressure monitoring (24h-ABPM). Regression models were adjusted for estimated glomerular filtration rate and change of antihypertensives.Results: 47 subjects were enrolled and the mean age was 57 (±14.6) years and 18 (38%) were female. In 43 randomized subjects with sufficiently performed 24h-ABPM neither systolic 24h-ABPM (2.522; 95%CI: −2.364, 7.408; mmHg) nor diastolic 24h-ABPM (0.868; 95%CI: −2.411, 4.147; mmHg) was affected by study group allocation. When looking at the effect of individual sodium bicarbonate dose on 24h-ABPM, the fully adjusted model suggested an increase of 0.047 (95%CI: −0.026, 0.119) mmHg by each mg/kg per day increase of sodium bicarbonate dose.Conclusion: Sodium bicarbonate supplementation over 8 weeks did not significantly increase blood pressure measured by 24h-ABPM in CKD patients.Trial Registration: EUDRACT Number: 2012-001824-36; 12/07/2012 (https://www.clinicaltrialsregister.eu).

Extracellular buffer choice influences acid-base responses and gastrointestinal symptoms

ABSTRACT To compare the bicarbonate kinetics and gastrointestinal (GI) symptom responses between an equal dose of sodium bicarbonate and sodium citrate using delayed-release capsules. Thirteen active males (age 20.5 ± 2.1 y, height 1.8 ± 0.1 m and body mass [BM] 76.5 ± 9.6 kg) consumed either 0.3 g.kg−1 BM sodium bicarbonate, sodium citrate or a placebo, using a double-blind, randomized crossover design. Blood bicarbonate ion (HCO3 −) concentration, pH and GI symptoms were measured pre-consumption and every 10 min for 180 min post-consumption. Blood HCO3 − concentration (P < 0.001) and pH (P = 0.040) were significantly higher in the sodium bicarbonate condition compared with sodium citrate condition up to 3 h post-consumption. Peak blood HCO3 – concentration was significantly higher with the sodium bicarbonate compared with citrate (P < 0.001). Mean GI symptom scores were lower (P = 0.037) for sodium citrate (1.5 ± 1.8 AU) than bicarbonate (2.6 ± 3.1 AU), with considerable inter-individual variability. No GI symptoms were reported following consumption of the placebo. Both substances increase HCO3 − values significantly, with sodium bicarbonate causing significantly higher pH and HCO3 − values than the same dose of sodium citrate, but results in slightly more severe GI symptoms.

Incidence of hyperkalemic RTA in pediatric post-renal transplant patients and the role of fludrocortisone.

One of the most common forms of post-transplant tubulopathy is hyperkalemic (RTA). The true incidence of hyperkalemic RTA in pediatric patients has not yet been studied. (CNIs) remain mostly blamed. Most cases are managed with sodium bicarbonate and potassium binding resins. Few studies have addressed the role of fludrocortisone in managing such patients. This study aimed to assess the efficacy and safety of fludrocortisone in the treatment of post-transplant hyperkalemic RTA. This is a retrospective cohort study of all pediatric (aged ≤16years) post-kidney transplant patients who were followed up in KFSH-D, Saudi Arabia from January 2015 until September 2019. A total of 136 pediatric post-renal transplant patients were reviewed, of these, 39 patients who were commenced on fludrocortisone post-transplant treatment and were followed up for at least 6months after fludrocortisone initiation were included in this study. The incidence of hyperkalemic RTA in our center was 60.6%. The medication requirements decreased significantly after fludrocortisone initiation. The median sodium bicarbonate dose decreased from 1.2mEq/kg/day (range, 0.0-4.7) prior to fludrocortisone treatment to 0.0mEq/kg/day (range, 0.0-4.3) at 6-month follow-up (p<.001). Similarly, the median (SPS) dose decreased from 1.2g/kg/day (range, 0.0-4.0) before fludrocortisone treatment to 0.0g/kg/day (range, 0.0-3.6) (p<.001) at 6-month follow-up. The initial mean potassium level 5.17mmol/L±0.61SD dropped to 4.60mmol/L±0.46SD at 6-month follow-up (p<.001). The initial mean serum bicarbonate level 22.31mmol/L±3.67SD increased to 24.5mmol/L±2.8SD at 6-month follow-up (p<.01). No effect on systolic and diastolic blood pressure was observed during follow-up. Hyperkalemic RTA incidence was high in our cohort. Fludrocortisone is safe and effective drug in the treatment of post-kidney transplant hyperkalemic RTA.

Assessment of Antigout, Antioxidant and Production Performance Augmenting Activity of Piper betle L. in Gout Induced Broiler Chicken

Background: The gout is commonly reported in birds and causes severe economic losses to the farmers. Hence to prevent the gout occurrence P.betle L. herb was selected and its antigout potential was studied in comparison with Allopurinol.Methods: The biological experiment was conducted with 120 broiler chicks and was divided into 5 treatment groups of 8 birds each with triplicate study for six weeks. The groups were control (T1), gout control (T2), Allopurinol (T3), P.betle L. - 10 g/kg (T4) and P.betle L. - 12.5 g/kg of feed (T5). The gout was induced using toxic dose of sodium bicarbonate in water (20 g/litre). The clinical signs and production performance were recorded and gross and histopathology studies were conducted. Serum biochemical parameters viz., uric acid and creatinine were periodically estimated (day 10, 15, 18 and 42 of trial) and anti-oxidant and xanthine oxidase enzyme activity were measured.Result: The production performances and the antioxidant activity were improved in P.betle L. groups and even better than Allopurinol. Also progressive reduction of uric acid and equivalent suppression of xanthine oxidase activity as that of Allopurinol were observed. Hence P.betle L. herb can be used effectively in the prevention of gout in birds.

Incidence and management of metabolic acidosis with sodium bicarbonate in the ICU: An international observational study

BackgroundMetabolic acidosis is a major complication of critical illness. However, its current epidemiology and its treatment with sodium bicarbonate given to correct metabolic acidosis in the ICU are poorly understood.MethodThis was an international retrospective observational study in 18 ICUs in Australia, Japan, and Taiwan. Adult patients were consecutively screened, and those with early metabolic acidosis (pH < 7.3 and a Base Excess < –4 mEq/L, within 24-h of ICU admission) were included. Screening continued until 10 patients who received and 10 patients who did not receive sodium bicarbonate in the first 24 h (early bicarbonate therapy) were included at each site. The primary outcome was ICU mortality, and the association between sodium bicarbonate and the clinical outcomes were assessed using regression analysis with generalized linear mixed model.ResultsWe screened 9437 patients. Of these, 1292 had early metabolic acidosis (14.0%). Early sodium bicarbonate was given to 18.0% (233/1292) of these patients. Dosing, physiological, and clinical outcome data were assessed in 360 patients. The median dose of sodium bicarbonate in the first 24 h was 110 mmol, which was not correlated with bodyweight or the severity of metabolic acidosis. Patients who received early sodium bicarbonate had higher APACHE III scores, lower pH, lower base excess, lower PaCO2, and a higher lactate and received higher doses of vasopressors. After adjusting for confounders, the early administration of sodium bicarbonate was associated with an adjusted odds ratio (aOR) of 0.85 (95% CI, 0.44 to 1.62) for ICU mortality. In patients with vasopressor dependency, early sodium bicarbonate was associated with higher mean arterial pressure at 6 h and an aOR of 0.52 (95% CI, 0.22 to 1.19) for ICU mortality.ConclusionsEarly metabolic acidosis is common in critically ill patients. Early sodium bicarbonate is administered by clinicians to more severely ill patients but without correction for weight or acidosis severity. Bicarbonate therapy in acidotic vasopressor-dependent patients may be beneficial and warrants further investigation.

Impact of sodium bicarbonate therapy on hemodynamic parameters in infants: a meta-analysis

Objective Sodium bicarbonate is a frequently used electrolyte for the acute treatment of metabolic acidosis in critically ill patients. We performed a systematic review and meta-analysis to determine the effect of sodium bicarbonate on hemodynamics, gas exchange and oximetry in critically children. Methods A systematic review of published manuscripts was conducted to identify studies of children who received sodium bicarbonate as part of the treatment for metabolic acidosis. A meta-analysis was then conducted to determine the impact of sodium bicarbonate on hemodynamics, gas exchange and oximetry. The following parameters were captured: base deficit, heart rate, mean arterial pressure, blood concentration of carbon dioxide, blood concentration of hydrogen ion, and pulse oximetry. Results A total of six studies with 341 patients were included in the analyses. All included studies were completed in critically ill infants with a mean age of 1.1 months. The mean dose of sodium bicarbonate was 1.7 meq/kg with a mean time of 67 min prior to repeat hemodynamics being collected after sodium bicarbonate administration. Base deficit significantly improved with a decrease of 2.80 (p = .001) and the partial pressure of carbon dioxide significantly decreased by a mean of −1.65 mmHg (p = .010). There was no change in heart rate, blood pressure, pH, partial pressure of oxygen, or saturation by pulse oximetry. Conclusion Sodium bicarbonate has a statistically significant but not clinically significant impact on partial pressure of carbon dioxide and base deficit 60 min after sodium bicarbonate administration in critically ill infants. There is no difference noted in pH, partial pressure of oxygen, or saturation by pulse oximetry.

Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study

BackgroundMetabolic acidosis is associated with accelerated progression of chronic kidney disease (CKD). Whether treatment of metabolic acidosis with sodium bicarbonate improves kidney and patient survival in CKD is unclear.MethodsWe conducted a randomized (ratio 1:1). open-label, controlled trial (NCT number: NCT01640119. www.clinicaltrials.gov) to determine the effect in patients with CKD stage 3–5 of treatment of metabolic acidosis with sodium bicarbonate (SB) on creatinine doubling (primary endpoint), all-cause mortality and time to renal replacement therapy compared to standard care (SC) over 36-months. Parametric, non-parametric tests and survival analyses were used to assess the effect of SB on these outcomes.ResultsA total of 376 and 364 individuals with mean (SD) age 67.8 (14.9) years, creatinine clearance 30 (12) ml/min, and serum bicarbonate 21.5 (2.4) mmol/l were enrolled in SB and SC, respectively. Mean (SD) follow-up was 29.6 (9.8) vs 30.3 (10.7) months in SC and SB. respectively. The mean (SD) daily doses of SB was 1.13 (0.10). 1.12 (0.11). and 1.09 (0.12) mmol/kg*bw/day in the first, second and third year of follow-up, respectively. A total of 87 participants reached the primary endpoint [62 (17.0%) in SC vs 25 (6.6%) in SB, p < 0.001). Similarly, 71 participants [45 (12.3%) in SC and 26 (6.9%) in SB, p = 0.016] started dialysis while 37 participants [25 (6.8%) in SC and 12 (3.1%) in SB, p = 0.004] died. There were no significant effect of SB on blood pressure, total body weight or hospitalizations.ConclusionIn persons with CKD 3–5 without advanced stages of chronic heart failure, treatment of metabolic acidosis with sodium bicarbonate is safe and improves kidney and patient survival.

The effects of sodium bicarbonate ingestion on cycling performance and acid base balance recovery in acute normobaric hypoxia

ABSTRACTThis study investigated the effects of two separate doses of sodium bicarbonate (NaHCO3) on 4 km time trial (TT) cycling performance and post-exercise acid base balance recovery in hypoxia. Fourteen club-level cyclists completed four cycling TT’s, followed by a 40 min passive recovery in normobaric hypoxic conditions (FiO2 = 14.5%) following one of either: two doses of NaHCO3 (0.2 g.kg−1 BM; SBC2, or 0.3 g.kg−1 BM; SBC3), a taste-matched placebo (0.07 g.kg−1 BM sodium chloride; PLA), or a control trial in a double-blind, randomized, repeated-measures and crossover design study. Compared to PLA, TT performance was improved following SBC2 (p = 0.04, g = 0.16, very likely beneficial), but was improved to a greater extent following SBC3 (p = 0.01, g = 0.24, very likely beneficial). Furthermore, a likely benefit of ingesting SBC3 over SBC2 was observed (p = 0.13, g = 0.10), although there was a large inter-individual variation. Both SBC treatments achieved full recovery within 40 min, which was not observed in either PLA or CON following the TT. In conclusion, NaHCO3 improves 4 km TT performance and acid base balance recovery in acute moderate hypoxic conditions, however the optimal dose warrants an individual approach.

Accidental Ricinus Communis Oil Cake Intoxication in a Dairy Cow

The aim of the study to report a case of spontaneous toxicity in a 5 year old Crossbred Jersey cow with a history of accidental ingestion of Ricinus communis oil cake during the month of November 2017. The animal had anorexia and profuse watery yellowish mucoid diarrhoea. On clinical examination the animal showed dullness and depression, congested conjunctival mucous membrane, tachycardia and doughy rumen with absence of rumen motility. The whole blood and sera samples were collected for haemato-biochemical analysis. The haematological values showed mild haemoconcentration with normocytic normochromic anaemia. There was no abnormality in biochemical values. Electrocardiography revealed sinus tachycardia. On ultrasound examination the liver and kidney showed normal contour and intestinal loops showed increased wall thickness without distension. The animal was treated with activated charcoal, egg white, fluid therapy, purgatives, antioxidants (Ascorbic acid) and low dose of sodium bicarbonate. The animal recovered uneventfully after three days of treatment. Recovery is generally less common in ricin poisonings.

Preventing EVAR Associated Acute Kidney Injury: The Optimal Strategy Remains Elusive

Preventing EVAR Associated Acute Kidney Injury: The Optimal Strategy Remains Elusive

The effect of metabolic alkalosis on the ventilatory response in healthy subjects

BackgroundPatients with acute respiratory failure may develop respiratory acidosis. Metabolic compensation by bicarbonate production or retention results in posthypercapnic alkalosis with an increased arterial bicarbonate concentration. The hypothesis of this study was that elevated plasma bicarbonate levels decrease respiratory drive and minute ventilation. MethodsIn an intervention study in 10 healthy subjects the ventilatory response using a hypercapnic ventilatory response (HCVR) test was assessed, before and after administration of high dose sodium bicarbonate. Total dose of sodiumbicarbonate was 1000 ml 8.4% in 3 days. ResultsPlasma bicarbonate increased from 25.2 ± 2.2 to 29.2 ± 1.9 mmol/L. With increasing inspiratory CO2 pressure during the HCVR test, RR, Vt, Pdi, EAdi and VE increased. The clinical ratio ΔVE/ΔPetCO2 remained unchanged, but Pdi, EAdi and VE were significantly lower after bicarbonate administration for similar levels of inspired CO2. ConclusionThis study demonstrates that in healthy subjects metabolic alkalosis decreases the neural respiratory drive and minute ventilation, as a response to inspiratory CO2.

Efficacy of Tricaine Methanesulfonate (MS-222) as an Anesthetic Agent for Short-term Anesthesia in Juvenile Yellow Perch (Perca flavescens)

The present study was conducted to assess an optimal dose of tricaine methansulfonate (MS-222) for rapid anesthesia and recovery in juvenile Yellow perch Perca flavescens. Yellow perch (≈7.0 g/fish) exposed to increasing concentrations of MS-222 (100, 150, 200, 250 and 300 mg/L) showed significant (P&lt;0.05) decreased anesthetic induction and increased recovery time with increasing MS-222 dose. Among the doses tested, the 250 mg/L MS-222 dose showed the shortest anesthetic induction and recovery times. Blood glucose and hematocrit levels were significantly (P&lt;0.05) lower in juvenile yellow perch exposed to the 250 mg/L MS-222 dose than the other MS-222 doses tested. Juvenile yellow perch (about 9.7 g/fish) exposed to 250/mg MS-222 combined with bicarbonate buffer at three ratios (w/w: 1:0.5, 1:1 and 1:2) showed significantly (P&lt;0.05) reduced anesthesia induction and recovery times. The shortest times of anesthesia induction and recover were observed in treatments using the 1:1 MS-222 to buffer ratio. Analysis on serum biochemical parameters (e.g., osmolality, glucose, albumin, calcium, alanine transaminase, total protein and calcium) showed that use of sodium bicarbonate with MS-222 did not have any significant effect on the above measurements compared with those determined in fish exposed to MS-222 only. Anesthesia induction time and recovery time of yellow perch were significantly affected by body sizes. These results suggest that a brief exposure to a 250 mg/L MS-222: sodium bicarbonate dose may be optimal for minimizing handling disturbance in juvenile yellow perch.

Pre-exercise optimisation of the alkalosis response to sodium bicarbonate ingestion: have we been missing its peak ergogenic effect?

The use of sodium bicarbonate (NaHCO 3 ) as an ergogenic aid has been widespread in athletic populations where high intensity, relatively short duration activity, is an important component of performance. The traditional ingestion time for this pre-exercise ergogenic buffering agent, is typically between 60-120 minutes before the start of exercise, using the most frequently ingested dose of 300 mg.kgBM -1 (McNaughton et al., 2016). This strategy has provided some equivocal data regarding the efficacy of the use of NaHCO 3 , in some sporting activities (Carr et al., 2012). However, a recent innovation using a personalised approach to the pre-exercise ingestion timing for NaHCO 3 (Miller et al., 2016; Sparks et al., 2017), may be more appropriate to achieve optimal ergogenic effects. The use of this technique has been shown to produce repeatable acid-base (Gough et al., 2017a) and performance responses (Gough et al., 2017b). More specifically, an individualised approach that synchronises the start of exercise with peak HCO 3 concentrations, appears to produce more consistent performance advantages over placebos in exercise bouts like 4 km cycling time trials (TT). This approach still suggests that doses of 300 mg.kgBM -1 are likely to be more ergogenic than 200 mg.kgBM -1 ones, but the associated gastrointestinal (GI) side effects that are exhibited in some athletes using higher doses may be ergolytic in extreme cases (Deb et al., 2018). Indeed, the GI symptoms are both difficult to predict and may vary between trials even with normal pre-exercise experimental dietary controls in place. Athletes, coaches, and performance nutrition professionals should therefore be aware of the potential ergogenic effect of NaHCO 3 , when individual time to peak has been accurately established, because it is likely larger than previously observed. However, caution and careful familiarisation with this ergogenic aid is essential to determine the severity of the potential ergolytic side effects that may preclude athletes from using it. Â Keywords: Ergogenic aid, performance, nutritional intervention, supplement. Â References Carr AJ, Slater GJ, Gore CJ, Dawson B, Burke LM (2012) Reliability and effect of sodium bicarbonate: buffering and 2000-m rowing performance. International Journal of Sports Physiology and Performance 7 (2):152-60. doi: 10.1123/ijspp.7.2.152 Â Deb SK, Gough LA, Sparks SA, McNaughton LR (2018) Sodium bicarbonate supplementation improves severe-intensity intermittent exercise under moderate acute hypoxic conditions. European Journal of Applied Physiology 118 (3):607-615 . doi: 10.1007/s00421-018-3801-7. Â Gough L, Deb S, Sparks SA, McNaughton LR (2017a) The Reproducibility of Blood Acid Base Responses in Male Collegiate Athletes Following Individualised Doses of Sodium Bicarbonate: A Randomised Controlled Crossover Study. Sports Medicine 47 (10):2117-2127. doi: 10.1007/s40279-017-0699-x. Â Gough L, Deb SK, Sparks SA, McNaughton LR (2017b) The reproducibility of 4 km time trial (TT) performance following individualised sodium bicarbonate supplementation: a randomised controlled trial in trained cyclists. Sports Medicine Open 3 (1) :34. doi: 10.1186/s40798-017-0101-4. Â McNaughton LR, Gough L, Deb S, Bentley D, Sparks SA (2016) Recent developments in the use of sodium bicarbonate as an ergogenic aid. Current Sports Medicine Reports 15 (4):233-44. doi: 10.1249/JSR.0000000000000283. Â Miller P, Robinson A, Sparks SA, Bridge CA, Bentley D, McNaughton LR (2016) The effects of novel ingestion of sodium bicarbonate on repeated sprint ability. Journal of Strength and Conditioning Research. 30 (2): 561-568. doi: 10.1519/JSC.0000000000001126. Â Sparks SA, Williams EL, Bentley D, Bridge CA, McNaughton LR (2017) Sodium bicarbonate ingestion and individual variability in time to peak pH. Research in Sports Medicine 25 (1):58-66. doi: 10.1080/15438627.2016.1258645.